Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix
Experience with substituting carboplatin for cisplatin is limited in advanced and recurrent cervix cancer and there has been no counterpart to GOG 158, which documented therapeutic equivalency of cisplatin/paclitaxel and carboplatin/paclitaxel for treatment of ovarian cancer, performed in a cervix cancer population.
Metastatic Carcinoma to the Uterine Cervix|Recurrent Carcinoma Cervix|Cervix Carcinoma Recurrent
DRUG: Paclitaxel and carboplatin|DRUG: Paclitaxel and carboplatin
Time to progression (length of time from start of chemotherapy to evidence of cancer progression., 6 months
Response rate, 6 months|Overall survival, 6 months|Quality Of Life Questionnaire, 6 months
This trial will be a prospective, randomized phase II pilot study. Consecutive patients of metastatic, recurrent or refractory carcinoma cervix enrolled in gynecology clinic at IRCH, AIIMS will be taken into study after taking informed consent. Patients will be randomized into two arms. Each arm shall contain 20 patients. The patients shall receive paclitaxel and carboplatin q3wk in first arm and paclitaxel and carboplatin q1 wk in second arm.